These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38488984)

  • 1. Performance of Eight Infliximab Population Pharmacokinetic Models in a Cohort of Dutch Children with Inflammatory Bowel Disease.
    Bevers NC; Keizer RJ; Wong DR; Aliu A; Pierik MJ; Derijks LJJ; van Rheenen PF
    Clin Pharmacokinet; 2024 Apr; 63(4):529-538. PubMed ID: 38488984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease.
    Bauman LE; Xiong Y; Mizuno T; Minar P; Fukuda T; Dong M; Rosen MJ; Vinks AA
    Inflamm Bowel Dis; 2020 Feb; 26(3):429-439. PubMed ID: 31287855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab in paediatric inflammatory bowel disease: External evaluation of population pharmacokinetic models.
    Heikal OS; van Rheenen PF; Touw DJ; Kosterink JGW; Maurer M; Koomen JV; Chelle P; Mian P
    Br J Clin Pharmacol; 2024 Sep; 90(9):2200-2214. PubMed ID: 38845210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of Infliximab Trough Concentrations in Inflammatory Bowel Disease Patients Using a Repeated-Measures Design.
    Santacana E; Rodríguez-Alonso L; Padullés A; Guardiola J; Bas J; Rodríguez-Moranta F; Serra K; Morandeira F; Colom H; Padullés N
    Ther Drug Monit; 2020 Feb; 42(1):102-110. PubMed ID: 31283556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of Polymorphisms and Other Biomarkers on Infliximab Exposure in Paediatric Inflammatory Bowel Disease: Development of a Population Pharmacokinetic Model.
    Clemente-Bautista S; Trocóniz IF; Segarra-Cantón Ó; Salvador-Marín S; Parramón-Teixidó CJ; Álvarez-Beltrán M; López-Fernández LA; Colom H; Cabañas-Poy MJ; Gorgas-Torner MQ; Miarons M
    Paediatr Drugs; 2024 May; 26(3):331-346. PubMed ID: 38507036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab Concentrations during Induction Are Predictive for Endoscopic Remission in Pediatric Patients with Inflammatory Bowel Disease under Combination Therapy.
    van Hoeve K; Seyed Tabib NS; Dreesen E; Tops S; Hoffman I; Gils A; Ferrante M; Vermeire S
    J Pediatr; 2022 Jan; 240():150-157.e4. PubMed ID: 34481805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab Maintenance Dosing in Inflammatory Bowel Disease: an Example for In Silico Assessment of Adaptive Dosing Strategies.
    Wojciechowski J; Upton RN; Mould DR; Wiese MD; Foster DJR
    AAPS J; 2017 Jul; 19(4):1136-1147. PubMed ID: 28444562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice.
    Buurman DJ; Maurer JM; Keizer RJ; Kosterink JG; Dijkstra G
    Aliment Pharmacol Ther; 2015 Sep; 42(5):529-39. PubMed ID: 26113313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of population pharmacokinetics to optimize the dosage regimen of infliximab in inflammatory bowel disease patients.
    Gil Candel M; Gascón Cánovas JJ; Gómez Espín R; Nicolás de Prado I; Rentero Redondo L; Urbieta Sanz E; Iniesta Navalón C
    Rev Esp Enferm Dig; 2020 Aug; 112(8):590-597. PubMed ID: 32686429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease.
    Grišić AM; Dorn-Rasmussen M; Ungar B; Brynskov J; Ilvemark JFKF; Bolstad N; Warren DJ; Ainsworth MA; Huisinga W; Ben-Horin S; Kloft C; Steenholdt C
    United European Gastroenterol J; 2021 Feb; 9(1):91-101. PubMed ID: 33079627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays.
    Barclay ML; Karim S; Helms ETJ; Keating PE; Hock B; Stamp LK; Schultz M
    Intern Med J; 2019 Apr; 49(4):513-518. PubMed ID: 30091273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of Population Pharmacokinetic Modeling for Individualized Infliximab Dosing Strategies in Crohn Disease.
    Frymoyer A; Hoekman DR; Piester TL; de Meij TG; Hummel TZ; Benninga MA; Kindermann A; Park KT
    J Pediatr Gastroenterol Nutr; 2017 Dec; 65(6):639-645. PubMed ID: 28471911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of Serum Infliximab Concentration by Point-of-care Devices in Children With Inflammatory Bowel Disease.
    Curci D; Lucafò M; Cifù A; Bramuzzo M; Martelossi S; Favretto D; De Pellegrin F; Fabris M; Vascotto F; Naviglio S; Ventura A; Stocco G; Decorti G
    J Pediatr Gastroenterol Nutr; 2019 Oct; 69(4):474-479. PubMed ID: 31149938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Model-Based Tool for Guiding Infliximab Induction Dosing to Maximize Long-term Deep Remission in Children with Inflammatory Bowel Diseases.
    Kantasiripitak W; Wicha SG; Thomas D; Hoffman I; Ferrante M; Vermeire S; van Hoeve K; Dreesen E
    J Crohns Colitis; 2023 Jun; 17(6):896-908. PubMed ID: 36661279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring.
    Lucidarme C; Petitcollin A; Brochard C; Siproudhis L; Dewitte M; Landemaine A; Bellissant E; Bouguen G
    Aliment Pharmacol Ther; 2019 Jan; 49(2):147-154. PubMed ID: 30589970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Mobile Infliximab Dosing Calculator for Therapy Optimization in Inflammatory Bowel Disease.
    Piester T; Frymoyer A; Christofferson M; Yu H; Bass D; Park KT
    Inflamm Bowel Dis; 2018 Jan; 24(2):227-234. PubMed ID: 29361094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab Trough Levels Are Not Predictive of Relapse in Patients with IBD in Endoscopic Remission: A Multicenter Cohort Study.
    Borren NZ; Paulides E; Frinack JL; Olson RN; Willrich MAV; van der Woude CJ; Ananthakrishnan AN
    Dig Dis Sci; 2021 Oct; 66(10):3548-3554. PubMed ID: 33037969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: A clinical validation.
    Berends SE; D'Haens GRAM; Schaap T; de Vries A; Rispens T; Bloem K; Mathôt RAA
    Br J Clin Pharmacol; 2019 Jul; 85(7):1544-1551. PubMed ID: 30927375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of infliximab therapy in inflammatory bowel disease using a dashboard approach-an Indian experience.
    Dave MB; Dherai AJ; Desai DC; Mould DR; Ashavaid TF
    Eur J Clin Pharmacol; 2021 Jan; 77(1):55-62. PubMed ID: 32803288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic Dashboard-Recommended Dosing Is Different than Standard of Care Dosing in Infliximab-Treated Pediatric IBD Patients.
    Dubinsky MC; Phan BL; Singh N; Rabizadeh S; Mould DR
    AAPS J; 2017 Jan; 19(1):215-222. PubMed ID: 27739008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.